Using Real-World Data to Inform Value-Based Contracts for Cell and Gene Therapies in Medicaid-Reference-Cited by-同舟云学术

Using Real-World Data to Inform Value-Based Contracts for Cell and Gene Therapies in Medicaid

Published:2023-11-21 Issue: Volume: Page:
ISSN:1170-7690
Container-title:PharmacoEconomics
language:en
Short-container-title:PharmacoEconomics

Author:

Zemplenyi Antal,Leonard Jim,DiStefano Michael J.,Anderson Kelly E.,Wright Garth C.,Mendola Nicholas D.,Nair Kavita,McQueen R. Brett

Funder

Colorado Department of Health Care Policy & Financing

Publisher

Springer Science and Business Media LLC

Subject

Public Health, Environmental and Occupational Health,Health Policy,Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s40273-023-01335-x.pdf

Reference37 articles.

1. Ma C-C, Wang Z-L, Xu T, He Z-Y, Wei Y-Q. The approved gene therapy drugs worldwide: from 1998 to 2019. Biotechnol Adv. 2020;40: 107502. https://doi.org/10.1016/j.biotechadv.2019.107502.

2. FDA. Approved cellular and gene therapy products. [Online]. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products. Accessed 1 Jun 2023.

3. Young CM, Quinn C, Trusheim MR. Durable cell and gene therapy potential patient and financial impact: US projections of product approvals, patients treated, and product revenues. Drug Discov Today. 2022;27(1):17–30. https://doi.org/10.1016/j.drudis.2021.09.001.

4. CVS Health. Latest look at projected gene therapies and approval timelines. 2022. [Online]. https://payorsolutions.cvshealth.com/sites/default/files/q2-2022-look-projected-gene-therapies-approval-timelines.pdf. Accessed 18 May 2023.

5. Baghdadi R. Medicaid best price. 2017. https://doi.org/10.1377/hpb20171008.000173.